<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MORPHINE LIKE ANTITUSSIVES" code="R05DA0-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical and electrocardiographic monotoring; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the frequency of the doses of methadone (2 to 3 times a day instead of once a day). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the methadone due to competitive blockage of the receptors.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine</COMMENT>
</INTERACTION>
</INTERACTIONS>
